Applications for AT-GAA Under Review in Europe

Applications for AT-GAA Under Review in Europe

313610

Applications for AT-GAA Under Review in Europe

The European Medicines Agency has accepted applications from Amicus Therapeutics seeking approval of AT-GAA, a two-component investigational therapy for the treatment of Pompe disease. “The acceptance of these filings is an important step forward for people living with Pompe disease and their families in Europe. Patients need new medicines as soon as possible,” John Crowley, chairman and CEO of Amicus, said in a press release. Per the EMA’s usual protocol, the applications now will be assessed…

You must be logged in to read/download the full post.